Clinical Trials in Greenslopes, Queensland
19 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Head and Neck Squamous Cell Carcinoma
Merus B.V.700 enrolled202 locationsNCT06525220
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled282 locationsNCT06925737
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled90 locationsNCT05020236
Recruiting
Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Uveal Melanoma
IDEAYA Biosciences520 enrolled94 locationsNCT07015190
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Bronchiectasis
Boehringer Ingelheim1,755 enrolled494 locationsNCT06872892
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
MelanomaNSCLCSolid Tumor, Adult+6 more
Nested Therapeutics, Inc230 enrolled23 locationsNCT06326411
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
MelanomaMetastatic MelanomaUnresectable Melanoma
Iovance Biotherapeutics, Inc.670 enrolled75 locationsNCT05727904
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Advanced Melanoma
Immunocore Ltd540 enrolled82 locationsNCT05549297
Recruiting
Phase 3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Advanced Melanoma
Immunocore Ltd680 enrolled211 locationsNCT06112314
Recruiting
Phase 2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Metastatic MelanomaUnresectable MelanomaMelanoma (Skin Cancer)
Iovance Biotherapeutics, Inc.100 enrolled5 locationsNCT07288203
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Metastatic MelanomaUnresectable MelanomaOcular Melanoma
Iovance Biotherapeutics, Inc.42 enrolled4 locationsNCT06940739
Recruiting
Phase 1Phase 2
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
ImmunotherapyColorectal Cancer MetastaticColorectal Cancer (CRC)+1 more
Anbogen Therapeutics, Inc.66 enrolled15 locationsNCT07244705
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Early Phase 1
AMT-676 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Multitude Therapeutics Inc.24 enrolled13 locationsNCT06400485